Atria Investments Inc Takes $122,000 Position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Atria Investments Inc purchased a new stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) during the 3rd quarter, Holdings Channel reports. The fund purchased 10,807 shares of the company’s stock, valued at approximately $122,000.

Other large investors have also made changes to their positions in the company. Centaurus Financial Inc. acquired a new position in Global X Genomics & Biotechnology ETF in the second quarter valued at about $146,000. James J. Burns & Company LLC acquired a new position in Global X Genomics & Biotechnology ETF in the second quarter valued at about $181,000. Insight Advisors LLC PA lifted its stake in Global X Genomics & Biotechnology ETF by 59.0% in the second quarter. Insight Advisors LLC PA now owns 21,177 shares of the company’s stock valued at $221,000 after buying an additional 7,861 shares during the period. Archford Capital Strategies LLC lifted its stake in Global X Genomics & Biotechnology ETF by 59.1% in the second quarter. Archford Capital Strategies LLC now owns 36,871 shares of the company’s stock valued at $385,000 after buying an additional 13,703 shares during the period. Finally, Sanctuary Advisors LLC acquired a new position in Global X Genomics & Biotechnology ETF in the second quarter valued at about $590,000. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Trading Up 2.5 %

NASDAQ:GNOM opened at $10.08 on Monday. Global X Genomics & Biotechnology ETF has a 1-year low of $9.52 and a 1-year high of $12.53. The business’s 50-day moving average price is $10.75 and its two-hundred day moving average price is $10.85. The firm has a market capitalization of $73.68 million, a price-to-earnings ratio of -4.31 and a beta of 1.03.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.